https://www.selleckchem.com/products/tr-107.html
Hypoxia is found in many solid tumors and is associated with increased disease aggressiveness and resistance to therapy. Reducing oxygen demand by targeting mitochondrial oxidative metabolism is an emerging concept in translational cancer research aimed at reducing hypoxia. We have shown that the U.S. Food and Drug Administration (FDA)-approved drug papaverine and its novel derivative SMV-32 are potent mitochondrial complex I inhibitors. We used a dynamic in vivo luciferase reporter system, pODD-Luc, to evaluate the impact of pharmacolog
Like
Comment
Share
